Projects per year
Personal profile
Education
- 2012 Ph.D., Pharmacology Institute, National Taiwan University
- 2003 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2025- Director, School of Pharmacy, Taipei Medical University
- 2023- Professor, Ph.D. Program in Clinical Drug Development of Chinese Herbal Medicine, Taipei Medical University
- 2023- Professor, Department of Pharmaceutical Sciences, Taipei Medical University
- 2023- Professor, Ph.D. Program in Biotechnology Research and Development, Taipei Medical University
- 2023- Professor, Department of Pharmaceutical Sciences, Taipei Medical University
- 2023- Professor, Ph.D. Program in Clinical Drug Development of Chinese Herbal Medicine, Taipei Medical University
- 2023- Professor, Master Program in Clinical Pharmacogenomics and Pharmacoproteomics, Taipei Medical University
- 2021-2023 Associate Professor, Ph.D. Program in Clinical Drug Development of Chinese Herbal Medicine, Taipei Medical University
- 2021-2023 Associate Professor, Department of Pharmaceutical Sciences, Taipei Medical University
- 2020-2023 Associate Professor, Ph.D. Program in Biotechnology Research and Development, Taipei Medical University
- 2019-2023 Associate Professor, Department of Pharmaceutical Sciences, Taipei Medical University
- 2018-2023 Associate Professor, Ph.D. Program in Clinical Drug Development of Chinese Herbal Medicine, Taipei Medical University
- 2015-2023 Assistant Professor, Master Program in Clinical Pharmacogenomics and Pharmacoproteomics, Taipei Medical University
- 2014-2018 Assistant Professor, Ph.D. Program in Clinical Drug Development of Chinese Herbal Medicine, Taipei Medical University
- 2013-2014 postdoc., Taipei Medical University
- 2012-2013 postdoc., National Taiwan University
Awards
- 2013 Outstanding Research Award for Scholar-in-Training, National Taiwan University
Research Interests
- Cancer Biology, Mechanism study of anticancer drugs
Related Link
Fingerprint
Dive into the research topics where Mei-Chuan Chen is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Investigating the Antitumor and Immunomodulatory Mechanisms of Steroidal Saponins in Bladder Cancer.
Chen, M.-C. (PI)
8/1/25 → 7/31/26
Project: A - Government Institution › b - National Science and Technology Council
-
海洋生物海綿萃取物對於膀胱癌細胞之抗癌機轉探討
Chen, M.-C. (PI)
7/1/25 → 2/28/26
Project: A - Government Institution › b - National Science and Technology Council
-
Investigating the Therapeutic Potential and Molecular Mechanisms of Terpenoids from Marine Sponge in Bladder Cancer
Chen, M.-C. (PI)
8/1/24 → 7/31/25
Project: A - Government Institution › b - National Science and Technology Council
-
華蟾素對於多形性膠質母細胞瘤細胞上 皮間質轉化之影響及抗癌機轉探討
Chen, M.-C. (PI)
7/1/24 → 2/28/25
Project: A - Government Institution › b - National Science and Technology Council
-
Investigating the Therapeutic Potential and Molecular Mechanisms of Terpenoids from Marine Sponge in Bladder Cancer
Chen, M.-C. (PI)
8/1/23 → 7/31/24
Project: A - Government Institution › b - National Science and Technology Council
-
Hinokiflavone is a novel CK2 inhibitor promoting apoptosis and synergizing with chemotherapeutic agents in cisplatin resistant bladder cancer cells
Hsieh, T. H., Kuo, H. P., Chen, M. C., Lin, Y. C., Lin, B. J., Hsu, K. C. & Chen, C. H., Dec 2025, In: Scientific Reports. 15, 1, 20922.Research output: Contribution to journal › Article › peer-review
Open Access1 Citation (Scopus) -
Personalized serum proteome profiles of COVID-19-associated acute respiratory distress syndrome in response to mesenchymal stem cell therapy
Putri, D. U., Chen, M. C., Weng, C. M., Kuo, H. P., Lee, C. H. & Han, C. L., 2025, In: Journal of Microbiology, Immunology and Infection.Research output: Contribution to journal › Article › peer-review
Open Access -
Correction to: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells (Cell Death & Disease, (2013), 4, 9, (e810), 10.1038/cddis.2013.330)
Chen, M. C., Chen, C. H., Wang, J. C., Tsai, A. C., Liou, J. P., Pan, S. L. & Teng, C. M., Jul 2024, In: Cell Death and Disease. 15, 7, 490.Research output: Contribution to journal › Comment/debate › peer-review
Open Access -
HSP90/LSD1 dual inhibitors against prostate cancer as well as patient-derived colorectal organoids
Tang, D. W., Chen, I. C., Chou, P. Y., Lai, M. J., Liu, Z. Y., Tsai, K. K., Cheng, L. H., Zhao, J. X., Cho, E. C., Chang, H. H., Lin, T. E., Hsu, K. C., Chen, M. C. & Liou, J. P., Nov 15 2024, In: European Journal of Medicinal Chemistry. 278, p. 116801 116801.Research output: Contribution to journal › Article › peer-review
7 Citations (Scopus) -
Syntheses of LSD1/HDAC Inhibitors with Demonstrated Efficacy against Colorectal Cancer: In Vitro and In Vivo Studies Including Patient-Derived Organoids
Chou, P. Y., Lai, M. J., Tsai, K. K., Cheng, L. H., Wu, Y. W., Chen, M. C., Pan, S. L., Ho, H. O., Nepali, K. & Liou, J. P., 2024, (Accepted/In press) In: Journal of Medicinal Chemistry. 67, 19, p. 17207-17225 19 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Citations (Scopus)
Datasets
-
Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms
Lai, M.-J. (Creator), Lee, C.-H. (Creator), Chao, Y.-H. (Creator), Mehndiratta, S. (Creator), Chen, M.-C. (Creator), Liou, J.-P. (Creator) & Lee, H.-Y. (Creator), Taylor & Francis, 2020
DOI: 10.6084/m9.figshare.13207104.v1, https://tandf.figshare.com/articles/journal_contribution/Effect_of_3-subsitution_of_quinolinehydroxamic_acids_on_selectivity_of_histone_deacetylase_isoforms/13207104/1
Dataset